Self-Adhering Magnetic Device to Treat Corneal Exposure

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversity of Illinois at Chicago

About this trial

Paralytic lagophthalmos can be difficult to treat and manage. It has a host of causes and effects, one of which (for the latter) is exposure keratopathy. Untreated, this can lead to corneal ulceration, inflammation, and potentially blindness. Despite a variety of attempts at treating this complex condition, none have satisfactorily reduced complications ranging from ease of use to aesthetics. With improvement in magnetic technology, however, that may change. Barmettler et al (2014) have demonstrated preliminary success of externally affixed magnets in closing both model and patient eyelids. As such, we hypothesize that magnetic devices can be used to treat corneal exposure by controlling eyelid position.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Males and females ages 18-80 years old.

Patients with recent corneal abrasion and no signs of infection in the examination

Patients with lagophthalmos

Normal Controls

Disqualifiers

Individuals with adhesive or tape allergies.

Individuals with a history of metal pieces/shavings embedded in the eye (such as from welding or metalworking)

Individuals with eye infections

Trial design

Design model

Single group

Treatments tested in this trial

  • temporary magnetic system for tarsorrhaphy (MST)

    Device

    cutting-edge technology has produced smaller magnets with stronger magnetic fields, prompting experts to revisit the use of magnets to facilitate eyelid closure

Treatment groups

25 Participants
are divided into 1 treatment group
Group A: Assess the performance of this novel eyelid closure device in vivoOther 1 intervention

Trial outcomes

Primary outcomes

1

Number of participants with success of a temporary magnetic system for tarsorrhaphy

Use of a temporary magnetic system for tarsorrhaphy (MST) to provide adequate closure of the eyes for ultimate use in conditions causing lagophthalmos (a disorder in eyelid closure)

Time frame
through study completion, an average of 3 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.